This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McLean, G. R. Articles by Ziltener, H. J. Search for Related Content PubMed PubMed Citation Articles by McLean, G. R. Articles by Ziltener, H. J.

Cobalamin Analogues Modulate the Growth of Leukemia Cells in Vitro¹

The Biomedical Research Centre [G. R. M., J. W. S., H. J. Z.] and Department of Medicine [J. W. S.] and Pathology and Laboratory Medicine [H. J. Z.], University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z3; Department of Radiation Oncology, University of Washington, Seattle, WA 98103 [P. M. P., D. S. W.]; and Receptagen Corp., Edmonds, WA 98020 [A. C. M., C. S. W.]

Analogues of cyanocobalamin (CN-Cbl), with functional groups attached to either the various propionamide groups of the corrin ring or to the ribose-nucleotide linker arm, have been evaluated in a cobalamin (Cbl)-dependent in vitro cell growth assay. In this bioassay, CN-Cbl supported, in a dose-dependent manner, the growth of the murine lymphoma BW5147 and the Cbl carrier protein, human apo-transcobalamin II, reduced the required concentration of Cbl by 100-1000-fold. Any chemical modification of Cbl decreased its ability to support cellular viability and proliferation, with several of the modifications abrogating activity completely. All of the Cbl analogues that promoted growth required the presence of apo-transcobalamin II for the optimal support of cell growth. Generally, Cbl analogues modified at the d-position of the corrin ring and, to a lesser degree, analogues modified at the b- position supported cell growth, whereas analogues with modifications at the e-position did not support cell growth. Mixing experiments demonstrated an inverse order of potency of Cbl analogues to inhibit cell growth. Thus, Cbl analogues with modifications at the e-position were potent inhibitors, whereas b-analogues exhibited only partial inhibitory activity at high molar excess, and d-analogues had no inhibitory activity at all. These results indicate that modifications at the e-position of Cbl abolish the ability of Cbl to support cell growth and generate potent inhibitors of Cbl-dependent cell growth.

¹ This work was supported by Receptagen Corp. and the Medical Research Council of Canada.

² To whom requests for reprints should be addressed, at The Biomedical Research Centre, 2222 Health Sciences Mall, University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z3. Phone: (604) 822-7834; Fax: (604) 822-7815; E-mail: hermann@brc.ubc.ca.

Received 3/26/97. Accepted 7/17/97.

This article has been cited by other articles:

				R. Waibel, H. Treichler, N. G. Schaefer, D. R. van Staveren, S. Mundwiler, S. Kunze, M. Kuenzi, R. Alberto, J. Nuesch, A. Knuth, et al. New Derivatives of Vitamin B12 Show Preferential Targeting of Tumors Cancer Res., April 15, 2008; 68(8): 2904 - 2911. [Abstract] [Full Text] [PDF]

				J. A. Bauer, B. H. Morrison, R. W. Grane, B. S. Jacobs, S. Dabney, A. M. Gamero, K. A. Carnevale, D. J. Smith, J. Drazba, B. Seetharam, et al. Effects of Interferon {beta} on Transcobalamin II-Receptor Expression and Antitumor Activity of Nitrosylcobalamin J Natl Cancer Inst, July 3, 2002; 94(13): 1010 - 1019. [Abstract] [Full Text] [PDF]

				W. B. Lott, S. S. Takyar, J. Tuppen, D. H. G. Crawford, M. Harrison, T. P. Sloots, and E. J. Gowans Vitamin B12 and hepatitis C: Molecular biology and human pathology PNAS, April 24, 2001; 98(9): 4916 - 4921. [Abstract] [Full Text] [PDF]